Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current and Emerging Infectious Risks of Blood Transfusions

Current and Emerging Infectious Risks of Blood Transfusions CONTEMPO UPDATES LINKING EVIDENCE AND EXPERIENCE Current and Emerging Infectious Risks of Blood Transfusions countries where resources are insuffi- antibody marker) than currently used Michael P. Busch, MD, PhD cient to enable basic infectious disease HCV antibody, HIV-1 antibody, and an- Steven H. Kleinman, MD donor screening. tigen assays. The window period for George J. Nemo, PhD HIV-1, using antibody assays, is ap- Major Viral Infections and proximately 22 days. The HIV-1 p24 an- Impact of Nucleic Acid Testing HE BLOOD SUPPLY IN THE UNITED tigen assay, which was introduced into States and other developed coun- The FIGURE summarizes progress dur- donor screening in 1995, reduced the Ttries has never been as safe as it ing the past 2 decades resulting in vir- window period to approximately 16 is now. During the past several de- tual elimination of transfusion- days. Current HIV-1 RNA minipool cades, there have been dramatic pro- transmitted major viral infections. NAT assays (for logistical and cost rea- gressive reductions in the risk of trans- Blood is now so safe that classic ap- sons NAT testing is currently per- fusion-transmitted clinically significant proaches to measure transfusion risk formed on minipools of plasma from blood-borne infections. This http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Current and Emerging Infectious Risks of Blood Transfusions

JAMA , Volume 289 (8) – Feb 26, 2003

Loading next page...
 
/lp/american-medical-association/current-and-emerging-infectious-risks-of-blood-transfusions-LEo5qv2lko
Publisher
American Medical Association
Copyright
Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.289.8.959
Publisher site
See Article on Publisher Site

Abstract

CONTEMPO UPDATES LINKING EVIDENCE AND EXPERIENCE Current and Emerging Infectious Risks of Blood Transfusions countries where resources are insuffi- antibody marker) than currently used Michael P. Busch, MD, PhD cient to enable basic infectious disease HCV antibody, HIV-1 antibody, and an- Steven H. Kleinman, MD donor screening. tigen assays. The window period for George J. Nemo, PhD HIV-1, using antibody assays, is ap- Major Viral Infections and proximately 22 days. The HIV-1 p24 an- Impact of Nucleic Acid Testing HE BLOOD SUPPLY IN THE UNITED tigen assay, which was introduced into States and other developed coun- The FIGURE summarizes progress dur- donor screening in 1995, reduced the Ttries has never been as safe as it ing the past 2 decades resulting in vir- window period to approximately 16 is now. During the past several de- tual elimination of transfusion- days. Current HIV-1 RNA minipool cades, there have been dramatic pro- transmitted major viral infections. NAT assays (for logistical and cost rea- gressive reductions in the risk of trans- Blood is now so safe that classic ap- sons NAT testing is currently per- fusion-transmitted clinically significant proaches to measure transfusion risk formed on minipools of plasma from blood-borne infections. This

Journal

JAMAAmerican Medical Association

Published: Feb 26, 2003

References